XM does not provide services to residents of the United States of America.
T
T

ThermoFisher


News

Bio-Techne meets Q4 profit estimates on demand for its diagnostics products

Bio-Techne meets Q4 profit estimates on demand for its diagnostics products Aug 7 (Reuters) - Bio-Techne TECH.O reported fourth-quarter profit in line with estimates on Wednesday as growth in the diagnostics and genomics unit offset weakness in its protein sciences unit. The Minnesota-based company posted an adjusted profit of 49 cents per share, meeting analysts' expectations according to LSEG data.
T

Leerink views Lilly and Sarepta as defensive stocks in turbulent market

BUZZ-Leerink views Lilly and Sarepta as defensive stocks in turbulent market ** Brokerages Leerink Partners says Eli Lilly LLY.N and Sarepta Therapeutics SRPT.O are among stocks it expects to outperform the broader market in "this turbulent period" of recession concerns ** Brokerage expects strong performance from the weight-loss and diabetes drug maker LLY on Wed, when it reports its earnings ** SRPT is a "a potential haven for investors seeking downside protection in a choppy market" due to po
A
B
M
T

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

UPDATE 1-Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims Adds response from Novartis in paragraph 3 By Blake Brittain Aug 5 (Reuters) - Novartis NOVN.S and Viatris VTRS.O were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
N
T

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims

Novartis, Viatris face new lawsuit over 'HeLa' cell misuse claims By Blake Brittain Aug 5 (Reuters) - Novartis NOVN.S and Viatris VTRS.O were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development. The estate of Henrietta Lacks accused Novartis and Viatris of unlawfully profiting from the use of the "HeLa" cells to create drugs that have been "integral to their market pre
N
T

China's stuttering recovery darkens global corporate growth outlook

ANALYSIS-China's stuttering recovery darkens global corporate growth outlook By Medha Singh Aug 2 (Reuters) - Global burger chains to car manufacturers are increasingly feeling the pinch from a faltering recovery in the world's No. 2 economy , China, and are strapping in for a bumpy ride ahead. A protracted downturn in the property market and high levels of job insecurity have knocked the wind out of a fragile recovery in China, a global trading powerhouse, and the effects of its slowdown can be
A
B
B
B
H
K
L
L
M
P
Q
S
T
T

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products

Bio-Rad Labs cuts annual revenue forecast on weak demand for diagnostics products Aug 1 (Reuters) - Bio-Rad Laboratories BIO.N cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics company fell 20% after the bell. Bio-Rad expects its full-year 2024 adjusted revenue to decline by about 2.5% to 4% on a currency-neutral basis, compared to its previous estimate of 1.0% to 2.5%.
T
W

Waters Corp cuts annual profit forecast on weak demand for lab equipment

Waters Corp cuts annual profit forecast on weak demand for lab equipment July 31 (Reuters) - Waters Corp WAT.N lowered its annual profit forecast as it anticipates reduced demand for its products and services used in drug development and research. Milford, Massachusetts-based Waters supplies lab equipment and technology for scientists across the world, with the majority of its revenue coming in from biopharma clients who use its tools for research and drug development.
T
W

Street View: Thermo's solid quarter signals easing demand weakness

BUZZ-Street View: Thermo's solid quarter signals easing demand weakness ** Thermo Fisher TMO.N raised its annual profit outlook on Wednesday and posted a better-than-expected profit in the second quarter, banking on improved demand for its tools and services used in clinical trials. SOLID QUARTER BY TMO SIGNALS RECOVERY ** RBC Capital Markets ("out
T

U.S. STOCKS Tesla, Lamb Weston, Blackstone Mortgage Trust

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq plummeted to a one-month low on Wednesday after Tesla and Alphabet disappointed with lackluster earnings, prompting investors to question if the Big Tech and AI-fueled 2024 equity rally was sustainable in the long run.
A
C
F
G
M
S
S
T
V
C
T
U
U
E
T
L
O

U.S. STOCKS FTAI Aviation, Check Point, Sage Therapeutics

BUZZ-U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Wednesday, with the tech-heavy Nasdaq leading declines after lackluster quarterly results from Tesla and Alphabet raised questions about the sustainability of the Big Tech and AI-led 2024 equity rally.
A
F
G
M
S
T
V
C
T
U
U
E
T
L
O

Thermo Fisher Scientific Inc reports results for the quarter ended in January - Earnings Summary

Thermo Fisher Scientific Inc reports results for the quarter ended in January - Earnings Summary Thermo Fisher Scientific Inc TMO.N reported quarterly adjusted earnings of $5.37​​ per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of $5.15. The mean expectation of twenty two analysts for the quarter was for earnings of $5.12 per share.
T

Nasdaq futures set to slide at open after Tesla, Alphabet disappoint

US STOCKS-Nasdaq futures set to slide at open after Tesla, Alphabet disappoint For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Visa falls after missing revenue growth forecasts AT&T rises after beating subscriber-addition estimates Enphase Energy, Texas Instruments up after results Rivian falls; will face trial in Tesla trade secrets theft case Futures down: Dow 0.45%, S&P 500 0.90%, Nasdaq 1.39% Updated at 8:27 a.m.
A
A
G
M
N
T
V
T
U
U
U
T

Thermo Fisher drops as raised profit forecast fails to impress Wall Street

REFILE-BUZZ-Thermo Fisher drops as raised profit forecast fails to impress Wall Street Corrects typo in company name in the headline ** Shares of medical equipment maker Thermo Fisher TMO.N down 3% at $535 premarket ** Co raises annual profit forecast to between $21.29 and $22.07 per share vs previous forecast of $21.14 to $22.02 ** Analysts were e
T

Futures slide after Tesla, Alphabet earnings disappoint

US STOCKS-Futures slide after Tesla, Alphabet earnings disappoint For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. AT&T rises after beating subscriber-addition estimates Enphase Energy, Texas Instruments up after results Visa falls after missing revenue growth forecasts Rivian falls; will face trial in Tesla trade secrets theft case Futures down: Dow 0.42%, S&P 500 0.69%, Nasdaq 1.04% Updated at 6:54 a.m.
A
A
G
M
N
T
V
T
U
U
U
T

Thermo Fisher lifts profit forecast as biotech demand shows signs of improvement

Thermo Fisher lifts profit forecast as biotech demand shows signs of improvement July 24 (Reuters) - Thermo Fisher TMO.N on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials. Contract drug manufacturers witnessed cut back on spending by their biotech clients in 2023 amid rising interest rates.
T

High earnings bar, Harris polling bump

MORNING BID AMERICAS-High earnings bar, Harris polling bump A look at the day ahead in U.S. and global markets from Mike Dolan Wall St has suddenly become a tough crowd to please. Much like last week's cool market reception for decent earnings beats from streamer Netflix NFLX.O or chipmaker TSMC 2330.TW , Alphabet's GOOGL.O surprisingly muscular second quarter left its stock down 2% overnight - and even the artificial intelligence theme didn't wow the gallery.
A
B
E
G
G
L
N
N
T
T
U
G
J
U
U
U
F
S
T
A
A
U

Thermo Fisher Q2 Adjusted EPS USD 5.37 Vs. IBES Estimate USD 5.12

BRIEF-Thermo Fisher Q2 Adjusted EPS USD 5.37 Vs. IBES Estimate USD 5.12 Jul 24 (Reuters) - Thermo Fisher Q2 EPS USD 4.04. Q2 adjusted EBIT USD 2,347 million vs. IBES estimate USD 2,304 million Q2 adjusted net income USD 2,057 million vs. IBES estimate USD 1,963 million Q2 revenue USD 10,541 million vs. IBES estimate USD 10,511 million outlook FY re
T

What to Watch in the Day Ahead - Wednesday, July 24

What to Watch in the Day Ahead - Wednesday, July 24 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Ford Motor is expected to post a drop in profit for the second quarter.
A
C
K
T
A
G
L

Thermo Fisher Scientific Inc <TMO.N> expected to post earnings of $5.12 a share - Earnings Preview

Thermo Fisher Scientific Inc expected to post earnings of $5.12 a share - Earnings Preview Thermo Fisher Scientific Inc TMO.N , TMO is expected to show a fall in quarterly revenue when it reports results on July 24 for the period ending June 30 2024 The Waltham Massachusetts-based company is expected to report a 1.7% decrease in revenue to $10.511 billion from $10.69 billion a year ago, according to the mean estimate from 19 analysts, based on LSEG data.
T

What to Watch in the Week Ahead and on Monday, July 22

What to Watch in the Week Ahead and on Monday, July 22 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY A meeting of the G20 finance ministers and central bank governors is scheduled to take place between July 22 and July 23, ahead of the G20 Brazil Summit 2024. The G20 finance ministe
A
B
C
G
M
T
V
C
H
T
G
L



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.